Loading
A Chinese study looking for small molecules in blood that could flag 13 different cancers.
Plasma metabolite markers for 13 cancers (NCT06363123) is an observational study sponsored by Beijing Friendship Hospital. It builds a plasma metabolite database for several cancers and develops and validates metabolic markers for early diagnosis.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 15 April 2024), with an estimated 2,700 participants, a start on 29 March 2024 and primary completion expected in October 2024.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/